FRANK E. MOTT to Head and Neck Neoplasms
This is a "connection" page, showing publications FRANK E. MOTT has written about Head and Neck Neoplasms.
Connection Strength
0.561
-
Advance Care Planning and End-of-Life Issues in Head and Neck Cancer. J Palliat Care. 2019 Jan; 34(1):18-20.
Score: 0.220
-
Genetic susceptibility to patient-reported xerostomia among long-term oropharyngeal cancer survivors. Sci Rep. 2022 04 22; 12(1):6662.
Score: 0.071
-
Phase 1/2a, open-label, multicenter study of RM-1929 photoimmunotherapy in patients with locoregional, recurrent head and neck squamous cell carcinoma. Head Neck. 2021 12; 43(12):3875-3887.
Score: 0.069
-
Pilot Phase II Trial of Neoadjuvant Immunotherapy in Locoregionally Advanced, Resectable Cutaneous Squamous Cell Carcinoma of the Head and Neck. Clin Cancer Res. 2021 08 15; 27(16):4557-4565.
Score: 0.068
-
Outcomes of patients with oropharyngeal squamous cell carcinoma treated with induction chemotherapy followed by concurrent chemoradiation compared with those treated with concurrent chemoradiation. Cancer. 2021 08 15; 127(16):2916-2925.
Score: 0.067
-
Cytotoxic and targeted systemic therapy in patients with advanced cutaneous squamous cell carcinoma in the head and neck. Head Neck. 2021 05; 43(5):1592-1603.
Score: 0.066